Form 4: Ironwood Pharmaceuticals Director Jay Shepard Reports Acquisition of Shares

Director Jay Shepard reports acquisition of Ironwood Pharmaceuticals shares as part of a non-employee director compensation policy.

Summary

• On June 18, 2024, Jay Shepard, a director of Ironwood Pharmaceuticals, acquired 24,311 shares of Class A Common Stock.
• The shares were acquired at a price of $0.
• Following the transaction, Shepard directly owns 126,555 shares of Ironwood Pharmaceuticals.
• The acquisition was made pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
• The restricted stock vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, which can be interpreted as a sign of confidence. However, it's a routine transaction related to compensation.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
• The grant of restricted stock aligns the director's interests with those of the shareholders.

Future Outlook

The restricted stock vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.

Industry Context

This filing is a routine disclosure related to director compensation and stock ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Director compensation policies involving stock grants are common across publicly traded companies, including pharmaceutical firms.
• Companies like Amgen, Gilead, and Biogen also utilize stock-based compensation to align director and shareholder interests.
• The vesting schedules and terms of these grants are typically disclosed in SEC filings.

Corporate Governance

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
• The compensation policy impacts the directors.

Key Dates